Pfizer
NYVEPRIA
Manufacturer:
Pfizer
Name:
NYVEPRIA
HCPCS Code Descriptor:
Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg
Category:
Q Code
HCPCS:
Q5122
NDC(s):
00069-0324-01
Primary Type:
Oncology Biosimilar Colony Stimulating Factor
Generic Status:
Single-Source
Route of Administration:
Subcutaneous
About:
NYVEPRIA is an Oncology Biosimilar Colony Stimulating Factor drug manufactured by Pfizer and administered via the Subcutaneous route of administration. The Q Code: Q5122 is aligned to the drug NYVEPRIA.
Nyvepria (pegfilgrastim) is a man-made protein that aids in the production of certain white blood cells (neutrophils). This medication can be used as a preventative measure to ensure that a patient doesn’t have a deficiency of neutrophils. Nyvepria is produced by Pfizer and is a biosimilar to the medication Neulasta (J2506). Nyvepria has been aligned to the HCPCS code Q5122 since January 2021.
Access Pricing and More By Registering
HCPCS Added Date:
1/1/21
HCPCS Effective Date:
4/1/23
HCPCS Short Description:
Inj, nyvepria
Billing and Coding Guide:
https://www.pfizerbiosimilarsresource.com/Video_PDF/PP-PEG-USA-0011_NYVEPRIA%20Billing%20and%20Coding%20Guide.pdf
Patient Assistance:
Not Found